An observational study in Advanced Breast Cancer, sponsored by Henan Cancer Hospital. Not yet recruiting at 1 site in China. Open to female participants. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Henan Cancer Hospital · Observational
To explore the duration of continued treatment for patients with advanced breast cancer who achieve complete response assessed by PET-CT after receiving systemic anti-tumor therapy.
Henan Cancer Hospital is the lead sponsor of 234 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with advanced breast cancer who achieved complete response (CR) assessed by PET-CT after receiving systematic anti-tumor therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Continue the original anti-tumor treatment regimen for 1 year
Continue the original anti-tumor treatment regimen for 2 years
Continue the original anti-tumor treatment regimen for 3 years
3-year PFS rate after treatment discontinuation
3-year progression-free survival (PFS) rate after treatment discontinuation. PFS was defined as the time from treatment discontinuation to first documented disease progression (PD) or death from any cause, whichever occurred first.
Time frame: 3 years after treatment discontinuation
1-year PFS rate after treatment discontinuation
1-year progression-free survival (PFS) rate after treatment discontinuation. PFS was defined as the time from treatment discontinuation to first documented disease progression (PD) or death from any cause, whichever occurred first.
Time frame: 1 year after treatment discontinuation
5-year PFS rate after treatment discontinuation
5-year progression-free survival (PFS) rate after treatment discontinuation. PFS was defined as the time from treatment discontinuation to first documented disease progression (PD) or death from any cause, whichever occurred first.
Time frame: 5 years after treatment discontinuation
OS
OS was defined as the time from initiation of best treatment to death for any cause; participants without death will be censored at the date of last follow-up.
Time frame: up to 5 years
QOL
Quality of Life (QOL) was defined as a comprehensive multi-dimensional index reflecting physical, psychological, social and environmental status. The FACT-B and GAD-7 scales will be used to assess patients' quality of life and influencing factors.
Time frame: up to 5 years
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.